Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To investigate predictors of cardiac morbidity in Valsartan treated high risk hypertensive patients with diabetes, new-onset diabetes and without diabetes : The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial

Next Previous
Trial Profile

To investigate predictors of cardiac morbidity in Valsartan treated high risk hypertensive patients with diabetes, new-onset diabetes and without diabetes : The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valsartan (Primary) ; Amlodipine
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms VALUE

    • Most Recent Events

    • 01 Apr 2019 Results published in the Blood Pressure
    • 11 Jun 2018 Results assessing blood pressure variability (n=14996) presented at the 28th European Meeting on Hypertension and Cardiovascular Protection.
    • 25 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top